UiPath Inc. (NYSE:PATH) Receives Consensus Recommendation of “Moderate Buy” from Analysts

UiPath Inc. (NYSE:PATH) has been given an average recommendation of “Moderate Buy” by the eighteen research firms that are presently covering the stock, Marketbeat reports. Nine investment analysts have rated the stock with a hold rating and nine have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $27.41.

Several equities analysts have recently weighed in on PATH shares. Evercore ISI raised their price target on shares of UiPath from $24.00 to $27.00 and gave the stock an “in-line” rating in a research note on Thursday, March 14th. Scotiabank raised their price target on shares of UiPath from $29.00 to $30.00 and gave the stock a “sector perform” rating in a research note on Thursday, March 14th. Wells Fargo & Company raised their price target on shares of UiPath from $24.00 to $25.00 and gave the stock an “equal weight” rating in a research note on Thursday, March 14th. Needham & Company LLC reissued a “buy” rating and issued a $30.00 price target on shares of UiPath in a research note on Wednesday, March 20th. Finally, Bank of America raised their price target on shares of UiPath from $26.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 14th.

UiPath Stock Down 0.6 %

PATH opened at $19.89 on Friday. The company has a market cap of $11.32 billion, a price-to-earnings ratio of -117.00 and a beta of 1.01. UiPath has a 52-week low of $13.30 and a 52-week high of $27.87. The firm’s fifty day simple moving average is $21.60 and its two-hundred day simple moving average is $21.78.

UiPath (NYSE:PATH) last posted its quarterly earnings data on Wednesday, March 13th. The healthcare company reported $0.06 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.04) by $0.10. The business had revenue of $405.25 million for the quarter, compared to the consensus estimate of $383.32 million. UiPath had a negative net margin of 6.87% and a negative return on equity of 3.29%. On average, research analysts forecast that UiPath will post -0.04 EPS for the current year.

Insider Buying and Selling at UiPath

In other UiPath news, CFO Ashim Gupta sold 40,000 shares of UiPath stock in a transaction dated Thursday, April 4th. The shares were sold at an average price of $21.66, for a total transaction of $866,400.00. Following the completion of the sale, the chief financial officer now directly owns 660,762 shares in the company, valued at $14,312,104.92. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders sold a total of 96,000 shares of company stock worth $2,023,440 over the last three months. Insiders own 31.03% of the company’s stock.

Institutional Investors Weigh In On UiPath

Institutional investors have recently made changes to their positions in the stock. Mark Sheptoff Financial Planning LLC acquired a new position in shares of UiPath in the fourth quarter valued at approximately $25,000. HighMark Wealth Management LLC acquired a new position in shares of UiPath in the fourth quarter valued at approximately $27,000. Cypress Capital Management LLC WY acquired a new position in shares of UiPath in the fourth quarter valued at approximately $29,000. ORG Partners LLC grew its holdings in shares of UiPath by 875.6% in the first quarter. ORG Partners LLC now owns 1,239 shares of the healthcare company’s stock valued at $27,000 after purchasing an additional 1,112 shares in the last quarter. Finally, GAMMA Investing LLC acquired a new position in shares of UiPath in the fourth quarter valued at approximately $36,000. 62.50% of the stock is currently owned by institutional investors and hedge funds.

UiPath Company Profile

UiPath Inc provides an end-to-end automation platform that offers a range of robotic process automation (RPA) solutions primarily in the United States, Romania, the United Kingdom, the Netherlands, and internationally. The company offers a suite of interrelated software to build, manage, run, engage, measure, and govern automation within the organization.